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Abstract
Recent characterization of hemangioblasts differentiated from human embryonic stem cells
(hESC) has further confirmed evidence from murine, zebrafish and avian experimental systems
that hematopoietic and endothelial lineages arise from a common progenitor. Such progenitors
may provide a valuable resource for delineating the initial developmental steps of human hemato-
endotheliogenesis, which is a process normally difficult to study due to the very limited
accessibility of early human embryonic/fetal tissues. Moreover, efficient hemangioblast and
hematopoietic stem cell (HSC) generation from patient-specific pluripotent stem cells has
enormous potential for regenerative medicine, since it could lead to strategies for treating a
multitude of hematologic and vascular disorders. However, significant scientific challenges
remain in achieving these goals, and the generation of transplantable hemangioblasts and HSC
derived from hESC currently remains elusive. Our previous work has suggested that the failure to
derive engraftable HSC from hESC is due to the fact that current methodologies for differentiating
hESC produce hematopoietic progenitors developmentally similar to those found in the human
yolk sac, and are therefore too immature to provide adult-type hematopoietic reconstitution.
Herein, we outline the nature of this challenge and propose targeted strategies for generating
engraftable human pluripotent stem cell-derived HSC from primitive hemangioblasts using a
developmental approach. We also focus on methods by which reprogrammed somatic cells could
be used to derive autologous pluripotent stem cells, which in turn could provide unlimited sources
of patient-specific hemangioblasts and HSC.
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Prospects for generating patient-specific hemangioblasts and HSC from
human pluripotent stem cells
Since Thomson and colleagues first isolated pluripotent human embryonic stem cells
(hESC) from the inner cell mass of preimplantation blastocyst embryos (Thomson et al.,
1998), hESC have been envisioned as an unlimited source for generating transplantable cell
lineages. Furthermore, because hESC can readily be manipulated and genetically altered
using transgenesis (Ma et al., 2003; Vallier et al., 2004) or homologous recombination
(Zwaka and Thomson, 2003; Urbach et al., 2004), these cell lines have great potential for
use in novel cellular therapies for a number of genetic and degenerative diseases, including
hematologic disorders. Despite increased efforts to match allogeneic transplant donors and
recipients, many patients fail to receive immunocompatible bone marrow, cord blood, or
peripheral blood stem cell transplants required for effective, long-term treatment of their
hematologic diseases (Grewal et al., 2003). As a result, the survival rate for most potentially
transplantable hematologic disorders remains low (Davies et al., 1995), and new sources of
transplantable, immunocompatible hematopoietic stemcells (HSC) are needed. A long
sought-after goal has been to generate large amounts of autologous, genetically corrected
HSC to treat severe hematologic diseases such as sickle cell anemia, thalassemia, and
leukemia. The recent scientific achievement of genetically-induced pluripotency of somatic
cells (e.g., from skin fibroblasts) has introduced the possibility that HSC generated from
patient-specific induced pluripotent stem cells (iPSC) will eventually meet this challenge.
The proof of principle for this approach was recently demonstrated in a murine model of
sickle cell hemoglobinopathy where iPSC were generated from sickle hemoglobin-affected
murine fibroblasts (Hanna et al., 2007). These studies showed that genetically-corrected
iPSC could generate normal, autologous transplantable HSC that could cure sickle cell
anemia in a murine model. Additionally, the efficient generation of unlimited supplies of
hemangioblasts with endothelial progenitor capacity from hESC and iPSC may also lead to
novel strategies for treating myocardial infarction, stroke, retinal blindness, and a multitude
of other vascular disorders.
The realization of these goals poses great scientific challenges, since the generation of
transplantable hemangioblasts and HSC from hESC or iPSC has not yet been efficiently
described. We previously showed that hESC differentiation produces blood cells similar to
those found in the human yolk sac (YS), which are too immature to provide adult-type
hematopoietic reconstitution. A sophisticated developmental biologic approach is necessary
for elucidating effective strategies that can differentiate hESC/iPSC into either early
mesoderm or YS-like hemangioblastic progenitors that can develop into transplantable HSC
that are found in the adult bone marrow.
In this review, we outline the challenges and opportunities for deriving hemangioblasts and
HSC from human pluripotent stem cells, and propose developmental strategies that could be
employed to generate hESC-derived HSC from primitive hemangioblasts ex vivo. We also
summarize the methods by which reprogrammed somatic cells can produce patient-specific
pluripotent stem cells, which subsequently could provide unlimited sources of autologous,
transplantable hemangioblasts and HSC.
Embryonic hemangioblasts sequentially develop into the adult
hematopoietic system
Classic anatomic observations of an intimate association between emerging embryonic
blood cells and vascular endothelium led to the hypothesis that they share a common
developmental precursor, termed the hemangioblast (Sabin, 1920; Murray, 1932). In mice
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and humans, two waves of hematopoieses form the blood system: primitive (yolk sac; YS)
and definitive (adult-type) hematopoieses. Hematopoietic progenitors derived from YS
blood islands are limited in their developmental capacity, and produce primarily primitive
erythroblasts. In contrast, the second, definitive wave of hematopoiesis generates long-term
engrafting lympho-hematopoietic HSC, which arise de novo from presumptive
hemangioblasts (via hemogenic endothelium) in the aortagonad-mesonephros (AGM) region
of the embryo (Medvinsky and Dzierzak, 1996; Cumano et al., 2001). These HSC migrate
from the AGM to fetal liver and bone marrow niches around birth in the mouse (Blazsek et
al., 2000), and at the end of the first trimester in the human fetus (Charbord et al., 1996),
where they sustain the adult’s lifetime blood generation.
In the mouse, hemangioblast formation is initiated by the ingress of pluripotent epiblast cells
through the primitive streak resulting in fate-committed mesodermal cells (Lawson et al.,
1991; Huber et al., 2004). These mesodermal populations within the primitive streak can be
divided into four subpopulations/tissue compartments (axial, paraxial, lateral plate, and
extraembryonic). The axial mesoderm, which consists of cells that ingress closest to the
most anterior region of the primitive streak, forms the notochord. The paraxial mesoderm,
which is created by cells that emerge in the anterior third region of the primitive streak,
generates the somites, and subsequently the vertebral column and skeletal muscles. The
lateral plate mesoderm, which is composed of cells in the middle of the primitive streak,
forms the circulatory system, gut wall, and the aorta-gonad mesonephros (AGM), which is
the major source of adult, definitive-type HSC. Finally, the extraembryonic mesoderm,
which is produced from cells that progress through the most posterior region of the primitive
streak, develops into (primitive) blood cells and the vasculature of the YS (Fig. 1A, B).
To date, there are only limited studies of early human hematopoietic development, and such
studies have suggested, but not confirmed, the existence of a similar bipotential human
hemangioblast (Cortes et al., 1999; Tavian et al., 1999a; Tavian et al., 2001; Oberlin et al.,
2002). Thus, despite substantial differences between human and mouse development (Tam
and Beddington, 1987; Beddington and Robertson, 1998), our understanding of the
mechanisms for the emergence of HSC from embryonic hemangioblasts is primarily derived
from studies of murine hematopoiesis. The ethical and technical difficulties associated with
studying human development have precluded the detailed characterization of a similar
hemangioblastic origin of human primitive and definitive hematopoiesis. Additionally, a
narrow repertoire of available human hemangioblastic surface markers has further
complicated the characterization of these rare progenitors in the human YS or AGM tissues,
which is currently available only in limited amounts.
Keller and colleagues originally demonstrated that mouse embryonic stem cells (mESC)
differentiated in a manner that recapitulated embryonic hematopoiesis through the
emergence of the hemangioblast (Wiles and Keller, 1991; Keller et al., 1993; Vittet et al.,
1996). mESC were differentiated into multi-lineage clusters of aggregated cells, called
embryoid bodies (EB), which contain elements of endoderm, mesoderm, and ectoderm
before maturing into more defined cell populations. If cultured in methyl-cellulose
containing hematopoietic growth factors, or co-cultured on bone marrow OP9 stromal cells
(Nakano et al., 1996), single EB cell progenitors differentiated into embryonic
hematopoietic progenitors. In particular, hematopoiesis initiated from a hemangioblastic,
clonogenic “blast-colony-forming cell” (BL-CFC), which was demonstrated not only during
mouse EB (mEB) differentiation (Kabrun et al., 1997; Kennedy et al., 1997; Choi et al.,
1998; Robertson et al., 2000; Lacaud et al., 2002; Fehling et al., 2003), but also in vivo
(Huber et al., 2004). This transient, VEGF-responsive progenitor normally arises in YS
blood island mesoderm, where it initiates vasculogenesis, as well as primitive and definitive
hematopoieses. Recent single-cell time-lapse microscopy imaging studies of mESC-derived
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mesodermal precursor differentiated on OP9 stromal cells, and their equivalent in vivo
counterparts from mouse embryos, have further confirmed the ability of hemangioblasts (or
hemogenic endothelial cells) to give rise to blood cells in real time (Eilken et al., 2009;
Lancrin et al., 2009). The emergence of this transient progenitor population was shown to be
regulated by SCL/Tal1, whereas further maturation into definitive hematopoietic cells
depended on Runx1/ AML1 (Lancrin et al., 2009).
In general, these YS-like, mEB-derived progenitors, however, have had limited engraftment
potential when injected into lethally-irradiated murine recipients (Potocnik et al., 1997;
Miyagi et al., 2002), although various degrees of maturation into definitive hematopoietic
progenitors could be accomplished by culture on AGM stroma (Byrne et al., 2007), or via
direct injection into the murine neonatal liver (Egami et al., 2003). These results indicate
that murine YS hemangioblasts can give rise to not only primitive YS hematopoiesis, but
may also possess the potential to mature and contribute to the definitive-type HSC
population which primarily develops in the AGM. Interestingly, ectopic mEB expression of
homeobox, and cell-cycling proto-oncogenes such as Hoxb4, Bcr/Abl, Stat5, and Cdx4, can
“program” YS-like mEB progenitors into definitive-like HSC capable of long-term
engraftment (Perlingeiro et al., 2001; Kyba et al., 2002; Kyba et al., 2003; Wang et al.,
2005). Unfortunately, similar experiments utilizing hESC differentiation did not result in
long-term engrafting, definitive HSC formation, possibly underscoring fundamentally
different developmental potentials between mice and humans (Wang et al., 2005a; Wang et
al., 2005).
We, and others, have described various methods for the hematopoietic differentiation of
hESC, including the derivation of human embryoid body (hEB) progenitors with
hemangioblastic potential (Kaufman et al., 2001; Chadwick et al., 2003; Cerdan et al., 2004;
Wang et al., 2004; Vodyanik et al., 2005; Zambidis et al., 2005; Vodyanik et al., 2006;
Zambidis et al., 2008). Our group described a hESC model that recapitulates the human YS
stages of embryonic hemato-endothelial development (Zambidis et al., 2005) (Fig. 1).
Hematopoietic activity was shown to arise in hEB cells from CD45− mesodermal-hemato-
endothelial (MHE) progenitors that give rise to hematopoietic blast colonies, followed by
two sequential YS-like primitive and definitive hematopoietic waves. We also delineated the
kinetics of hEB differentiation in serum-free conditions for the emergence of a putative
common hemangioblastic progenitor responsible for these two waves. Hematopoietic
colony-forming cell (CFC) potential of hEB cells differentiated in serum-free medium with
hematopoietic growth factors showed that 6–9 day old hEB vigorously initiated YS-like,
primitive and definitive hematopoieses. Primitive foamy macrophages and large nucleated
erythroblasts expressing exclusively embryonic and fetal hemoglobins were observed during
days 7–12 of hEB differentiation. This was followed by YS-like definitive erythropoiesis
(that had limited amounts of adult hemoglobin; Fig. 2), myelopoiesis, and megakaryopoiesis
typical of a late YS stage of development at days 12–20 of hEB development. Progressive
expression of SCL/TAL1, RUNX1/AML1, GATA1, and GATA2 (genes known to play
roles in the initiation of hematopoiesis from murine hemangioblasts) during this period
indicated that this hEB-derived model recapitulated early embryonic hematopoietic
development.
Although these detailed kinetic studies of hEB differentiation predicted the emergence of a
hemangioblastic progenitor, they did not demonstrate this stem-progenitor in a clonal
manner. In contrast to murine experimental systems, the clonal characterization of human
hemangioblasts that give rise to such primitive and definitive hematopoieses has been
hindered by several obstacles, including 1) inefficient methods for hematopoietic
differentiation of hESC, 2) the lack of an accurate prospective hemangioblast surface
marker, and 3) the absence of a quantitative, robust human BL-CFC assay, that was recently
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described (Kennedy et al., 2007; Zambidis et al., 2008). Furthermore, although KDR/flk-1
(VEGFR2) is a cell surface marker of populations containing murine hemangioblasts, it
appears to be less specific for specifying rare hemangioblasts in human tissues, and is
expressed abundantly in a majority of differentiating hEB cells, as well as during normal
human embryonic development (Carpenter et al., 2003; Kennedy et al., 2007; Zambidis et
al., 2008). The identification of more specific markers for human hemangioblasts, or
hemogenic endothelium will greatly facilitate the ultimate experimental goal of efficiently
deriving HSC from them.
ACE (CD143) expression marks the emergence of a clonogenic, hESC-
derived hemangioblastic progenitor of primitive and definitive YS-like
hematopoieses
Using a monoclonal antibody (mAb BB9) specific for the somatic isoform of surface
angiotensin-converting enzyme (ACE/ CD143), Simmons and colleagues identified a
primitive subset of NOD-SCID mouse-engrafting CD34+ HSC in adult bone marrow,
mobilized peripheral, and umbilical cord blood. Moreover, in rare 30-day-old human
embryonic tissues, ACE (CD143) was shown to mark emergent HSC in the human YS,
intra-embryonic subaortic patches of the AGM, and fetal liver (Ramshaw et al.,2001;
Jokubaitis et al., 2008). The embryonic pattern of human ACE expression is consistent with
a dorsal emigration of ACE+CD34− hemangioblasts from the paraaortic splanchnopleura,
and subsequent colonization of the ventral aspect of the dorsal aorta to give rise to CD34+
hemogenic endothelial cells.
Our group extended these studies and used the ACE/CD143 marker to specifically identify
hESC-derived clonogenic hemangioblasts that can initiate both primitive and definitive YS-
like hematopoieses (Zambidis et al., 2008), similar to that observed in mEB differentiation
and murine embryos (Kennedy et al., 1997; Huber et al., 2004). Using a serum-free BL-CFC
assay supplemented with BMP4, VEGF, FGF2/heparan sulfate and TPO, single
ACE+CD34+/− hEB cells generated blast colonies containing multilineage endothelial-
primitive-definitive hematopoietic progenitors (Fig. 3A). On secondary re-culture assays,
these multipotent blast colonies generated YS-like GlyA+CD71+CD45− erythroid cells, and
endothelium (if re-cultured on stromal-free conditions), or alternatively definitive-type
CD45+ erythromyeloid cells (if re-cultured on OP9 bone marrow stroma (Fig. 3A)).
Interestingly, our hEB differentiation system appears to recreate hematopoietic events in
vitro which normally occur during the first weeks of human embryonic development, and
that are likely initiated with mesodermal commitment to a YS hemangioblast (Fig. 1). In
murine embryos, hemangioblasts first appear in the posterior region of the primitive streak
(Huber et al., 2004), and in vitro mEB differentiation is generally considered an
experimental surrogate for these post-implantation developmental events. Similarly, the
developmental kinetics of our hEB-derived mesodermal-hemato-endothelial (MHE) clusters,
and ACE+ BL-CFC mirror the emergence of hemangioblasts that presumably arise
following human primitive streak formation at days 12–13 with a remarkably congruent
timeline (FIGURE 1D, E). Similarly, normal YS blood island generation at gestational days
14–16 was recapitulated by an hEB-derived wave of primitive hematopoiesis, followed by a
definitive wave of erythromyelopoesis, which normally occurs at gestational days 18–20
(prior to the onset of fetal circulation at day 21). These results suggested that our hEB-based
differentiation system serves as an in vitro model to study the earliest developmental steps in
human hematopoietic genesis.
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The renin-angiotensin system may dictate embryonic hemangioblast
lineage differentiation
The discovery that angiotensin converting enzyme (ACE/ CD143) marks primitive
embryonic hemangioblasts raised the possibility that the versatile renin-angiotensin system
plays a critical role in regulating the earliest stages of human hemato-endothelial
differentiation, as it does in avian embryos (Savary et al., 2005). In adults, the renin-
angiotensin axis regulates blood pressure and water balance via hormonal secretion of
angiotensin II (Ang II) peptide. Ang II is the proteolytic product of a series of enzymatic
processes that begin with the cleavage of angiotensinogen by renin to yield the catalytic
substrate of the ACE, angiotensin I (Ang I), which is ultimately converted to Ang II (Paul et
al., 2006). Renin-angiotensin system signaling is subsequently mediated by angiotensin II
type 1 and 2 receptors (AGTR1/AGTR2), which are locally expressed in all important sites
of emerging angio-hematopoiesis including the YS, liver, kidney, embryonic aorta, and
retinal/choroid regions (Schutz et al., 1996). Notably, while AGTR1 is expressed
constitutively from development to adulthood where it functions as a key regulator of the
cardiovascular system through G-protein-coupled interactions, AGTR2 is rarely expressed
in adult tissues (Grady et al., 1991; Akishita et al., 1999), suggesting a key role during early
development.
In our studies (Zambidis et al., 2008), we demonstrated a dramatic upregulation of AGTR2
during expansion of hEB-derived ACE+ hemangioblasts, which suggests a unique role for
the renin-angiotensin axis in guiding the initial developmental phases of human angio-
hematopoiesis (Hubert et al., 2006; Heffelfinger, 2007). Indeed, we found that hEB-derived
BL-CFC could be directed to differentiate into either hematopoietic or endothelial progeny
by manipulating signaling pathways normally mediated by the renin-angiotensin axis.
Firstly, enzymatic ACE activity was required for hEB-derived hemangioblast expansion
since the specific ACE inhibitor Captopril dramatically blocked BL-CFC formation,
suggesting a requirement for Ang II peptide synthesis, and/or downstream AGTR signaling.
Moreover, manipulation of angiotensin II signaling with either AGTR1- or AGTR2-specific
inhibitors resulted in pronounced deviations of hEB differentiation toward either
endothelium, or multipotent hematopoietic progenitors. For example, specific blockade of
AGTR1 signaling with Losartan significantly boosted hEB-derived hematopoietic colony-
forming cells (CFC) formation, especially the generation of multipotent mixed CFC. To
determine if AGTR inhibitors acted either directly on hemangioblast expansion, or via
indirect amplification of more committed progenitors, we included these blockers in
clonogenic BL-CFC assays. Secondary replating of AGTR1-inhibited (Losartan) blast
colonies produced predominately he-matopoietic cell lineages, with limited endothelial
differentiation. In contrast, replating of blast colonies treated with an AGTR2-specific
inhibitor (PD123–319) resulted in predominantly endothelial progeny, with limited
hematopoietic differentiation. Thus, AGTR2 function was necessary for expansion of
hemangioblast colonies into multipotent hematopoietic progenitors, and its inhibition with
PD123–319 completely abolished hematopoietic differentiation, while imposing an almost
exclusive endothelial fate on hemangioblast colonies.
Since AGTR2 signaling is known to antagonize AGTR1 signaling directly (Hubert et al.,
2006), our data implicated a general mechanism by which emerging hemangioblasts in the
YS or AGM may be directed to differentiate by the hematopoietic stem cell niche. One
hypothesis is that antagonistic competition between AGTR2 and AGTR1 for Ang II binding
on emerging hemangioblasts directs their development into either hematopoietic
progenitors, or alternatively into vascular-endothelial networks. Finally, these studies
suggest that manipulation of AGTR2 signaling could be an important strategy, in general,
for expanding multipotent hematopoietic progenitors from primitive HSC. We speculated
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that AGTR1/ AGTR2-regulated stem cell proliferation may be a generalized phenomenon,
since AGTR1 inhibition by Losartan was reported to increase skeletal muscle regeneration
in patients with primary muscular dystrophies (Cohn et al., 2007), and the renin-angiotensin
axis critically influences normal fetal development, since both ACE and AGTR1 receptor
blockers are teratogenic. AGTR2 signaling, in particular, is known to regulate cellular
growth and apoptosis during vascular and neural development (Grammatopoulos et al.,
2005; Savary et al., 2005). Interestingly, mutations of AGTR2 have been reported in patients
with severe mental retardation and autism (Vervoort et al., 2002), thus further substantiating
a role for the renin-angiotensin system in directing the proper development of the nervous
system.
Generation of engraftable definitive adult-type HSC may require
developmental maturation of mesodermal precursors in specific
mesenchymal stromal niches
Although we initially demonstrated that hESC, like mESC, primarily model the
developmental steps associated with primitive YS extra-embryonic hematopoiesis, it is not
yet clear if hESC differentiation can model the definitive, AGM-like lympho-hematopoiesis
that normally arises from the intra-embryonic AGM. EB or stromal-based differentiation
protocols described thus far have shown that both mESC and hESC-derived hematopoietic
progenitors have a YS molecular and cellular phenotype with limited long-term engrafting
potential in adult recipients (Potocnik et al., 1997; Matsuoka et al., 2001; Miyagi et al.,
2002), which is a defining feature only of AGM-derived HSC. Since YS progenitors can be
conditioned into engrafting, definitive HSC following co-culture on appropriate stromal
niches (Matsuoka et al., 2001), these hematopoietic progenitors may be inherently deficient
in a “definitive HSC instructive program” that can be provided only by an in vivo
mesenchymal AGM, fetal liver, or bone marrow niche. We recently demonstrated that
hESC-derived CD34+ cells committed in culture into hemato-endothelial cell progenitors
could be further developed into mature blood and vascular cells following transplantation
into chicken embryo yolk sacs (Park et al., 2009). These observations not only demonstrated
the utility of the avian embryo as a convenient and reliable host to model the
angiohematopoietic development of hESC, but they also underscored the importance of
evaluating how in vivo niches can mature primitive progenitors into adult hematopoiesis.
Extensive experimental evidence has suggested that mesenchymal stromal niches are
regulators of the native adult HSC niche. Bone morphogenetic protein (BMP)-responsive
mesenchymal stromal cells (MSC), for example, are found in hematopoietic sites during
ontogeny, and are key components of the HSC-supportive micro-environmental niche by
activating, or differentiating into supportive cells (e.g., osteoblasts). Osteoblasts, in turn,
express Notch ligands (e.g. Jagged1) and can increase HSC numbers via niche-mediated
Notch signaling (Noort et al., 2002; Angelopoulou et al., 2003; Arai et al., 2004;
Bensidhoum et al., 2004; Sammons et al., 2004; Koch et al., 2005; Martin and Bhatia, 2005;
Mendes et al., 2005; Adams et al., 2006; Francois et al., 2006; Friedman et al., 2006;
Muguruma et al., 2006; Suzuki et al., 2006). Notch signal transduction may be critical in
determining definitive HSC maturation and expansion, and mediates multiple key cell fate
decisions via the lateral inhibition of cell fate mechanism, or inductive signaling. NOTCH1
and NOTCH2 are expressed in adult human CD34+ HSC, and their ligand JAGGED1 is
expressed on bone marrow osteoblasts, suggesting direct involvement in the regulation of
HSC by the stromal microenvironment (Calvi et al., 2003; Zhang et al., 2003; Taichman,
2005; Wilson and Trumpp, 2006). Although the Notch pathway plays a major role in
lymphopoietic lineage decisions, its role in the genesis and maintenance of HSCs is only
beginning to emerge. Embryonic Notch1−/− knockout mice have severely impaired
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hematopoiesis (Kumano et al., 2003) due to an inability of hemangioblasts in the AGM
region to differentiate into definitive HSC. In contrast, mEB-based studies showed that the
Notch−/− phenotype does not affect YS hematopoiesis, whereas AGM-type definitive HSC
generation is defunct (Hadland et al., 2004; Robert-Moreno et al., 2005), and likely depends
on a Notch-Runx1 interaction.
Indeed, Notch-Runx1 signaling may be central to the initial “executive” decision-making
process that generates definitive murine HSC at its embryonic AGM origin. There is
abundant evidence that Runx1 is a key regulator of definitive HSC emergence in the AGM,
where it is indispensable for formation of long-term engrafting CD45+c-kit+ HSC (North et
al., 1999; North et al., 2002). Runx1 binds DNA as a heterodimer with CBFβ, and neither
Runx1−/− nor CBFβ −/− mutant embryos can develop definitive HSCs (Okuda et al., 1996;
Wang et al., 1996). In contrast, targeted deletion of Runx1 in adult mice leads to
hematopoietic abnormalities but preservation of HSC (North et al., 1999; Nakagawa et al.,
2006). While other factors associated with hematopoietic emergence, such as the bHLH
factor SCL (Robb et al., 1995; Shivdasani et al., 1995), play critical roles in both primitive
and definitive hematopoieses, only Runx1 is uniquely required for the emergence of
definitive, long-term engrafting HSCs. In human embryos, control of a NOTCH-RUNX1
axis may simply be mediated by regulating the expression of Notch proteins per se.
NOTCH-1, 2, 4, and ligands DELTA1–4, and JAGGED1, for example, are not expressed in
human YS sites, but expression appears later in the fetal liver when fetal definitive HSCs
first expand (Dando et al., 2005).
Multiple lines of evidence now support the concept that primitive hematopoietic progenitors,
such as those generated from ESC can develop into an adult definitive phenotype with
appropriate stromal contact. For example, co-culture of hESC on primary stromal cells
derived from murine embryonic day E10.5 AGM, or E12.5 fetal liver stromal cell lines
significantly increased definitive CFC activity (Krassowska et al., 2006; Ledran et al.,
2008). AGM stromal cell lines, in particular enhanced hematopoietic mesoderm
differentiation with subsequently increased hematopoietic progenitor cell formation. Direct
cell-cell contact and paracrine signaling with stroma was necessary to mature hESC into
definitive hematopoietic cell lineages since conditioned media and extracellular matrix from
these stromal cell lines alone abolished or significant reduced definitive CFC activity. These
studies suggested a role for TGFβ1 and TGFβ3 in definitive hematopoietic induction.
Nonetheless, evidence for generation of a true adult AGM-type definitive HSC has not yet
been conclusively demonstrated in these recently published methodologies (Tian et al.,
2006; Ledran et al., 2008). Similar to previous reports (Wang et al., 2005a), erythropoiesis
generated from engrafted cells in these latter studies was still at an embryonic/fetal stage.
Furthermore, primary engraftment in immunodeficient murine recipients remained low,
short-term (<3 months), displayed limited lymphopoiesis, and had low subsequent
secondary engraftment frequencies. These characteristics of poor lympho-hematopoietic
engraftment are consistent with hESC-derived progenitors possessing an embryonic YS, and
not adult-type definitive phenotype.
Another study, using preimmune fetal sheep recipients of hEB-derived CD34+CD38−
Lin38− cells demonstrated low levels of human hematopoietic cell long-term primary and
secondary transplant engraftment potential (0.05%–0.2%; evaluated at 10–39 months post
injections) (Narayan et al., 2006). Since the bone marrow of these fetal recipients was not
conditioned (e.g., with irradiation or busulfan) prior to cell transplantation, however, it is
unclear whether the low engraftment frequency observed would be sufficient to expand or
ensure their survival postnatally.
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To further elucidate the role of mesenchymal stromal niches in generation of definitive
HSC, our group has begun related experiments, as those described above. We co-cultured
FACS-purified ACE+CD34+-derived hemangioblasts from differentiated day 9–10 hEB onto
E12.5–E14.5 murine fetal liver (FL) stroma (Fig. 3B–D), or human MSC (hMSC), and
supplemented these cultures with human hematopoietic growth factors. Under these
conditions, purified YS-like ACE+CD34+ hemangioblasts differentiated into “cobblestone”-
appearing CD34+CD45+CD38− cells that produced abundant definitive-type CFU (GM-
CFC, G-CFC, M-CFC, GEMM-CFC, BFU-e, CFU-e) in methylcellulose assays. These
hematopoietic colonies were indistinguishable from cord blood CD34+ cell colony controls
(Fig. 3B, C). hEB-derived erythroid CFU-e, for example, were indistinguishable from CB
CFU-e in both morphology, and in their expression patterns of adult hemoglobin with low
intracytoplasmic embryonic globin (epsilon), and high amounts of neonatal/adult gamma
and beta globin expression, in comparison to hEB-derived CFU-e that persist in their
expression of embryonic globins (Fig. 3C). More importantly, these stroma-differentiated
hEB cells are only capable of short-term (evaluated at 12 weeks), multilineage lympho-
erythromyeloid engraftment following injection into the neonatal livers of highly
immunodeficient, irradiated NOD/SCID/IL2Rgnull (NOG) mice (Fig. 3C). These pilot
experiments strongly suggest that a proper hematopoietic microenvironment (e.g., as
provided by hMSC osteoblastic or FL-type stroma), can indeed pattern YS-like hEB
progenitors into at least short-term (12 weeks) engraftable, adult-type progenitors.
In summary, although unclear at this time, in vitro generation of engraftable definitive HSC
may require a recreation of their in vivo stem cell niche milieu. As illustrated above, a better
understanding of the relevant growth factors and signaling molecules that activate definitive
HSC-specific genes from primitive progenitors is needed. Experiments that define the
critical components of the definitive HSC niche will probably also rely on additional
methods for enhancing the homing of these ex vivo-generated HSC following
transplantation and engraftment into conditioned recipients.
The role of homeobox (HOX)-regulating factors (CDX, MLL) in determining
definitive HSC genesis and self-renewal
Although multiple factors such as BMP4, activin A, VEGF, FGF2, Hedgehog, TPO, and
Wnt factors are implicated in the generation and downstream self renewal of HSC from
mesoderm (Johansson and Wiles, 1995; Bhatia et al., 1999; Faloon et al., 2000; Baron,
2001; Dyer et al., 2001; Lako et al., 2001; Li et al., 2001a; Adelman et al., 2002; Byrd et al.,
2002; Murdoch et al., 2002; Perlingeiro et al., 2003; Reya et al., 2003; Willert et al., 2003),
the upstream molecular “switch” for patterning hematopoietic mesoderm into HSC remains
obscure, yet vital for understanding how to differentiate hESC toward adult-type definitive
HSC. Multiple studies have suggested that the regulated control of HOX genes may be the
effectors for this upstream “definitive HSC-genesis” switch. Thus, in addition to patterning
hESC-derived cells into definitive HSC by recapitulating hematopoietic stem cell niches,
manipulation of HOX gene expression may also serve a role in generating long-term
engraftable HSC from pluripotent stem cells.
HOX proteins are a highly-conserved group of transcription factors characterized by a 60-
amino acid DNA-binding motif termed the homeodomain. HOX genes are organized into
four major genomic clusters (A, B, C, D), and play crucial roles in embryonic
organogenesis. Clusters A-C are expressed at high levels in normal HSC, and have been
widely implicated in HSC self-renewal and regulation. Notably, HOXB4 has been exploited
for its ability to expand engraftable human HSC (Antonchuk et al., 2002). Additionally,
multiple HOX genes participate as leukemic translocation partners, or are dysregulated in
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leukemias with normal karyotypes (Antonchuk et al., 2002; Owens and Hawley, 2002; Grier
et al., 2005), further implicating their role in HSC self-renewal.
Loss-of-function studies have shown that most HOX genes have redundant functions,
whereas gene disruption of upstream HOX-regulators such as MEIS1, PBX1, MLL, and
CDX genes results in severe hematopoietic phenotypes (Yu et al., 1995; Antonchuk et al.,
2002; Owens and Hawley, 2002; Davidson et al., 2003; Krosl et al., 2003; Abramovich and
Humphries, 2005; Davidson and Zon, 2006), suggesting that these genes directly regulate
HSC genesis or expansion. HOX regulation by the highly conserved CAUDAL family of
genes (CDX1, CDX2, and CDX4) (Chawengsaksophak et al., 2004; Shimizu et al., 2006)
was recently established. CDX genes encode a family of homeodomain transcription factors
that regulate anterior-posterior embryonic patterning by orchestrating the specific expression
of HOX genes during ectodermal and mesodermal development (Epstein et al., 1997;
Charite et al., 1998; Reece-Hoyes et al., 2005). The normal embryonic expression pattern of
cdx4, for example, appears to be tightly regulated in Xenopus (Reece-Hoyes et al., 2005),
zebrafish (Rawat et al., 2004), and mouse development (Gamer and Wright, 1993; Horn and
Ashworth, 1995; Epstein et al., 1997; Charite et al., 1998; Rawat et al., 2004). Cdx4 is first
detected in the posterior embryo during gastrulation and somitogenesis, and its expression
domains in lateral plate mesoderm include the hematopoietic-initiating tissues of the
allantois and early YS wall cells (which also co-express scl).
Cdx2 and cdx4 function are likely redundant, yet critical for patterning mesoderm to
primitive hematopoietic lineages. Zebrafish “kugelig” cdx4-mutants (Davidson et al., 2003),
showed that cdx4 makes posterior mesoderm competent for subsequent hematopoietic
commitment (possibly at the hemangioblast stage) by upregulating target Hox genes HoxA6,
HoxB3, HoxB4, HoxB8, and HoxC6. Additionally, cdx1a and cdx4 (redundantly) regulate
the genesis of downstream runx1a+ definitive HSC derived from the AGM region
(Davidson and Zon, 2006), thus implicating a role of cdx genes in both primitive and
definitive hematopoieses. These zebrafish studies reveal a novel vertebrate cdx-hox axis that
may act as the long-sought-after instructive signal for HSC genesis from a hemangioblast.
Indeed, Daley’s group recently strengthened this hypothesis by generating transplantable,
multi-lineage HSC via retroviral co-expression of both Cdx4 and Hoxb4 in mEB progenitors
(Wang et al., 2005). In contrast, dysregulated expression of Cdx genes results in various
malignancies (Chawengsaksophak et al., 1997; Rawat et al., 2004) over-expression of Cdx2/
Cdx4 is leukemogenic either alone (Bansal et al., 2006), with fusion partners (Rawat et al.,
2004), or most potently when co-expressed with HOX cofactors (Bansal et al., 2006).
Although our group reported CDX4 expression in primitive hEB-derived hematopoietic
progenitors (Zambidis et al., 2005), human CDX function remains technically difficult to
study, since CDX expression is restricted to embryonic development. Interestingly, a recent
report described CDX4 overexpression in human acute leukemias with both normal
karyotypes or t(9;11) MLL fusions (Bansal et al., 2006). The mixed lineage leukemia (MLL)
proto-oncogene is a better-characterized HOX-regulator than CDX. MLL is a histone
methyltransferase involved in recurrent (11q23) translocations found in ~80% of infant and
10% of adult leukemias (Tkachuk et al., 1992; Corral et al., 1993; Yu et al., 1998; Hess,
2004; Eguchi et al., 2005). These aggressive leukemias often have biphenotypic myeloid-
lymphoid markers, and a very poor prognosis (Poirel et al., 1996; Pui et al., 2002). The N-
terminal portion of MLL is known to be fused in-frame to over 40 known (apparently
disparate) leukemogenic fusion partners that all elaborate a common pathologic motif:
aberrant activation of HOX genes via direct transcriptional activation (Joh et al., 1996;
Dobson et al., 1999; Joh et al., 1999; Ayton and Cleary, 2003; Cozzio et al., 2003; Ferrando
et al., 2003; Forster et al., 2003; Johnson et al., 2003; Martin et al., 2003; Rozovskaia et al.,
2003; Zeisig et al., 2004; Milne et al., 2005a; Milne et al., 2005b; Chen et al., 2006; Kong et
al., 2006; Krivtsov et al., 2006; Meyer et al., 2006; Somervaille and Cleary, 2006). The
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normal wildtype MLL gene encodes a Trithorax-group chromatin regulator essential in Hox-
mediated body specification (Yu et al., 1995), but also specifically necessary for definitive
lympho-hematopoietic stem cell genesis (Fidanza et al., 1996; Hess et al., 1997). Mll−/−
mouse embryos and mEB have revealed a crucial role for Mll in definitive HSC
development in the AGM (Ernst et al., 2004a; Ernst et al., 2004b). Although primitive
hemangioblast development appears intact in differentiating Mll−/− mEB, downstream
definitive-type progenitors from mEB or AGM regions are deficient, and correlate to a
paucity of Hox gene upregulation. Engraftable AGM-derived HSC, for example, could not
be generated from Mll−/− murine embryos, although ectopic expression of Cdx4 in Mll−/−
mEB partially rescues their hematopoietic deficiency, thus implicating a potential Cdx-Mll-
Hox axis. A better understanding of a CDX4-MLL-HOX axis in humans may reveal
efficient strategies for expanding definitive HSC from primitive hEB-derived progenitors.
Manipulation of HOX gene expression to derive engraftable hESC-derived hematopoietic
progenitors has already been reported, but with limited success compared to murine ESC
systems. Generation of long-term engraftable hematopoietic cells from mouse ESC-derived
cells using ectopic Hoxb4/Cdx4 expression (Kyba et al., 2002; Wang et al., 2005a), for
example, raised the possibility that similar studies could result in the derivation of definitive
HSC from hESC (Wang et al., 2005b). While HOXB4 vector-transduced hEB-derived
progenitors generated a ~2.5 fold increase in hematopoietic cell expansion, it did not lead to
the maturation of hESC-derived hematopoietic cells into long-term engraftable HSC as was,
in contrast, shown in mice. This discrepancy between mESC and hESC systems remains
unresolved, although it remains possible that other HOX-regulating factors such as MLL or
CDX are more potent than HOXB4 for maturing hESC-derived cells into definitive HSC.
Moreover, there are likely many other undiscovered HOX-related factors that might play
important roles for patterning definitive HSC from primitive hemangioblasts, although the
search for such factors should be tempered by the concomitant oncogenicity that ectopic
HOX factor expression inevitably results in. In fact, expression analysis of other genes
important for HSC physiology, behavior, self-renewal, and in vivo maintenance has already
revealed major differences between hESC-derived and adult hematopoietic progenitors.
hESC-derived hematopoietic progenitors, for example, express high levels of cell-cycle
proteins, and reduced levels of expression of genes important in stem cell self-renewal. In
contrast, adult somatic HSC show upregulation of multiple genes involved in quiescence and
HSC renewal such as cyclin G2, p53 binding protein, p21, and p57 (Wang et al., 2005b).
Definitive, long-term engraftable HSC may arise from distinct mesodermal
precursors of a different origin than the YS hemangioblast
Although it was originally suggested that the same population of HSC found in the
embryonic YS also supplied the fetus and adult (Weissman et al., 1978), it is now generally
accepted that the majority of adult-type blood-forming stem cells likely arise independently
from endothelium-associated cell clusters localized on the ventral aspect of the dorsal aorta
and vitelline artery in the AGM (e.g., between days 27–40 for human development; (Tavian
et al., 1999a)). These CD34+CD31+CD45+CD38− endothelium-adherent cells yield long-
term hematopoietic, myeloid and lymphoid cells, while their counterparts in the YS only
produce erythro-myeloid lineages (Tavian et al., 1996; Tavian et al., 1999b; Tavian et al.,
2001).
Nonetheless, the developmental origins of adult HSC that arise from the AGM currently
remains elusive. The majority of YS hematopoietic progenitors likely survive only long
enough to support organogenesis in the rapidly developing embryo. In contrast, HSC
generated within the aortic floor (e.g., via hemogenic endothelium), or from mesenchymal
cells within the subaortic patches, or perhaps directly from a non-mesenchymal lateral plate
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mesoderm-derived hemangioblastic progenitor (Fig. 1A) likely provide the long-term source
of adult hematopoiesis (Jaffredo et al., 2005).
Although murine AGM-derived progenitors show long-term engraftment properties and
recapitulation of the entire adult blood system when injected into the bone marrow of
lethally-irradiated adult mice (Medvinsky and Dzierzak, 1996; Cumano et al., 2001), it has
not been excluded that the primitive hemangioblast (derived from extraembryonic
mesoderm, and which dictates ephemeral YS hematopoiesis) could also contribute to the
definitive HSC population found in the adult to some extent. Several studies have suggested
the possibility that blood-forming stem cell clusters originating in the YS subsequently
mature as they transverse through the embryo to the AGM, where they initiate definitive
HSC formation. Recent studies, for example, using an inducible lacZ cell-labeling system
which genetically marked YS-derived Runx1/ Aml1+ cells, proposed that adult HSC in
murine bone marrow originate from a combination of progenitors derived from ancestral
extraembryonic mesoderm-derived YS blood islands, and lateral-plate mesoderm-derived
AGM blood stem cell clusters (Samokhvalov et al., 2007; Ueno and Weissman, 2007). At
E7.5 of mouse development, the expression of Runx1 (which is crucial for hematopoietic
emergence) is limited in expression only to cells found in the YS, since vascular cell
trafficking connections between the YS and the embryo have not yet been established.
Intriguingly, the genetic tracking of these Runx1+ cells for up to a year in the adult,
demonstrated that these YS-derived cells could contribute to the adult HSC population
found in the bone marrow (albeit in limited amounts (~1–10%)). These results indicate that
YS blood progenitors can, indeed, play a role in contributing to the pool of adult, long-term
reconstituting lympho-hematopoietic stem cells.
In summary, the spatial separation of the extraembryonic mesoderm and lateral plate
mesoderm that form primitive and definitive hematopoiesis respectively, raises the
possibility that two types of mesoderm may produce qualitatively different hemangioblasts
with differing cell lineage potentials, gene expression patterns, and perhaps epigenetic
changes (Fig. 1A, B). It remains to be seen whether the hESC-derived YS-like
hemangioblasts we have described can be further matured into definitive HSC by means of
recreating their natural in vivo microenvironments. An alternative approach is to devise
hESC differentiation strategies that generate lateral plate/AGM-type mesoderm, rather than
YS-type extraembryonic mesoderm. Toward this end, the mouse model has provided
numerous insights into methods for improving lateral plate mesoderm differentiation based
on a complex signalling network that directs epiblast patterning and primitive streak
formation (Tam and Beddington, 1987; Ang and Constam, 2004). In particular, the key
regulators of in vivo mesodermal induction, which we review below, would have to be
recapitulated in vitro.
Targeted use of mesodermal morphogens may enhance the efficiency of
hemangioblast and HSC generation from human pluripotent stem cells
A better understanding of the signaling pathways and growth factor environments that
differentiating hESC are exposed to may guide enhanced mesodermal differentiation, and
subsequent hemangioblast-HSC generation. Specifically, a detailed map of mesodermal
transcriptional control could lead to the formation of an in vitro system that can specifically
direct cellular differentiation into either extraembryonic (YS), or lateral plate (AGM)
mesoderm, and thus give rise to distinct types of hematopoietic progenitors. For example,
the duration, location and concentration of key selected signaling pathways (e.g., NODAL,
TGFβ, WNT, and FGF) are thought to play critical roles in the development of distinct
mesodermal populations during primitive streak formation (Ben-Haim et al., 2006). Below,
we briefly review the known mechanisms of some of these key morphogens, which we
PETERS et al. Page 12
Int J Dev Biol. Author manuscript; available in PMC 2012 November 30.
$watermark-text
$watermark-text
$watermark-text
suggest will have to be properly manipulated in vitro for proper hESC mesodermal-
hemangioblast differentiation.
NODAL establishes the proximal-distal axis and mesoendoderm specification of the
embryo
NODAL expression is first detected in the inner cell mass and primitive endoderm at mouse
embryonic day E4.5 (Varlet et al., 1997), where it maintains the expression of the
pluripotency markers Pou5f1(Oct4) and Nanog in the epiblast (Mesnard et al., 2006). In
addition to a role in pluripotency, NODAL is also required for primitive streak formation
(Conlon et al., 1994). Around E5.0, a subset of visceral endoderm at the distal tip of the
embryo responds to NODAL signalling by expressing a specific repertoire of genes
(Brennan et al., 2001) including the NODAL antagonists, Lefty1 (Perea-Gomez et al., 1999)
and Cer1(Belo et al., 1997). The combination of a proximally located source of NODAL and
a distally located source of NODAL antagonists creates a gradient of NODAL signalling
with highest expression at the extraembryonic/epiblast boundary (Lu et al., 2004). Around
E5.5 the Cer1 and Lefty1-expressing cells migrate anteriorly, rotating the area of NODAL
inhibition, which results in higher NODAL signalling in the posterior part of the embryo
(Kimura et al., 2000; Perea-Gomez et al., 2002; Yamamoto et al., 2004). Loss of NODAL
signalling leads to the absence of anterior primitive streak mesoderm derivatives and
definitive endoderm (Beck et al., 2002; Yamamoto et al., 2004). In contrast, elevation of
NODAL signaling due to transcriptional loss of a co-repressor or expression of a NODAL
antagonist, results in the over-expression of mesodermal markers (Meno et al., 1999; Perea-
Gomez et al., 2002). In hESCs, a role for NODAL in maintaining pluripotency, and
inhibiting neuroectodermal differentiation (Vallier et al., 2004; Smith et al., 2008; Wu et al.,
2008) has been described, but its role in mesoendoderm differentiation has not yet been
deciphered, but will likely be dependent on the duration and magnitude of NODAL
signaling (Vincent et al., 2003).
Activin A, although dispensable for mouse gastrulation (Matzuk, et al., 1995), binds to the
same receptors as NODAL, and is thought to mimic some of its activities. In Xenopus,
exogenous activin A is well-characterized as a mesoderm inducer (Ariizumi et al., 1991).
Indeed, activin A has been used to improve hESC differentiation into mesodermal lineages
(Schuldiner et al., 2000; Burridge et al., 2007; Yang et al., 2008), although its addition to
hESCs also conversely induced endodermal, rather than mesodermal lineages (Levenberg et
al., 2003; D’Amour et al., 2005; Hay et al., 2008; Ishii et al., 2008), requiring the
suppression of PI3K signaling through insulin/IGF inhibition (McLean et al., 2007). This
apparent paradox in activin A activity may likely be explained by dose dependent effect, as
seen in Xenopus animal caps, where lower concentrations promote mesodermal lineages,
and higher concentrations promote endodermal lineages (Okabayashi and Asashima, 2003).
As with NODAL, the use of activin A to maintain hESC pluripotency has also been
described (Beattie et al., 2005; James et al., 2005; Xiao et al., 2006).
BMP4 signals from the extra embryonic ectoderm induce mesoderm formation
The high levels of NODAL expression in the proximal epiblast at E5.0 also maintain BMP4
expression in extraembryonic ectoderm adjacent to the epiblast (Brennan et al., 2001; Ben-
Haim et al., 2006). BMP4 is required for mesoderm formation and patterning (Winnier et al.,
1995) and acts by inducing WNT3 expression in the proximal epiblast (Liu et al., 1999). The
distal visceral endoderm that expresses NODAL inhibitors also expresses WNT3 inhibitors
such as DKK1, which similarly results in the movement of WNT3 expression towards the
posterior epiblast (Glinka et al., 1998; Kemp et al., 2005). It is at this pregastrulation stage
that the expression of mesoendodermal markers such as T (Wilkinson et al., 1990), Mixl1
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((Pearce and Evans, 1999), Eomes (Ciruna and Rossant, 1999), and Gsc (Blum et al., 1992)
is detected.
Fibroblast Growth Factors (FGFs) control mesoderm pattering and maintenance
In contrast to NODAL, FGFs control the specification of and maintenance of mesoderm
rather than primary mesoderm induction (Burdsal et al., 1998; Ciruna and Rossant, 1999).
Mutational analyses of the known Fgf genes have demonstrated that only Fgf4 and Fgf8 are
required for early embryonic development (Niswander and Martin, 1992; Crossley and
Martin, 1995; Ciruna and Rossant, 1999; Sun et al., 1999). Although FGF2 has a well
established role in maintaining hESC pluripotency, when hESC are differentiated and FGF
receptor signalling is inhibited by SU5402, hEBs demonstrate a significant reduction in
expansion by day 4 and <1% cell survival by day 8 (Vallier et al., 2005). Additionally, a
dominant negative FGFR2 abrogated the formation of the primitive ectoderm layer in mEBs
by affecting basement membrane formation, and mEBs became necrotic after 6–8 days (Li
et al., 2001b). These results suggest that FGF2 signalling is essential for EB growth and
development.
Unpatterned mesoderm expresses KDR/flk-1 (VEGFR2) (Ema et al., 2006), and PDGFRA,
the alpha receptor of platelet derived growth factor (Takakura et al., 1997). Lateral plate
mesoderm, which forms the hematopoietic lineages, subsequently downregulates PDGFRA,
whereas paraxial mesoderm downregulates KDR (Sakurai et al., 2006). In addition, the
expression of KDR/flk-1 is maintained in hemangioblasts and HSC (Ziegler et al., 1999).
Furthermore, the addition of VEGFA during mESC hematopoietic differentiation has been
shown to enhance the effects of BMP4 (Nakayama et al., 2000; Park et al., 2004). Similarly,
abundant insulin growth factor 2 (IGF2) expression in gastrulating mouse embryo
mesoderm, and an impairment of in vitro mesoderm differentiation of Igf2−/− mESC,
suggested that IGF2 plays an important role in the induction of mesoderm during
development. Addition of exogenous IGF2 to in vitro cultures of Igf2−/− differentiating
mESC rescued mesoderm formation and expression of mesodermal markers (Morali et al.,
2000)
Our group has already begun to test the effects of these critical morphogens on hEB
hematopoietic lineage generation using our novel serum-free hEB differentiation system.
We recently described that, in the absence of serum, the minimal combination of VEGFA,
BMP4, and FGF2/heparan (VBF2) was necessary and sufficient for efficiently inducing
hematopoiesis in differentiating hESC (Zambidis et al., 2008). Further supplementation of
mesodermal morphogens such as NODAL, WNT3A, IGF2, or activin A to developing hEB
appeared to mimic some of the in vivo mesoderm-enhancing effects described above (Fig.
4). In particular, the addition of NODAL to the minimal VBF2 combination led to a
significant increase of total hematopoietic CFC, multipotent CFC, and primitive and
definitive erythrocytes, in comparison to VBF2 alone. Addition of WNT3A, a downstream
effector of NODAL, to VBF2 also modestly increased the same populations of
hematopoietic cells with the exception of definitive erythrocytes, suggesting that this factor
primarily enhances the formation of primitive YS cells. Likewise, addition of IGF2 to VBF2
augmented only modestly the total formation of hematopoietic CFC, multipotent CFC, and
primitive and definitive erythroid CFC, although this combination appeared to greatly
enhance myeloid lineage differentiation. Our current efforts are focused on isolating distinct
mesodermal progenitors from these optimized morphogen-treated hEB cultures, and
assaying their primitive and definitive hematopoietic potential.
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Role of microRNAs in pluripotency and directed differentiation of hESC
into hemangioblasts and HSC
MicroRNAs (miRNAs) have recently been found to play critical roles in embryonic
differentiation and developmental timing of cellular differentiation, including hematopoietic
lineage specification. MiRNAs are small, approximately 22 nucleotide-long noncoding
RNAs that post-transcriptionally regulate gene expression (Lee et al., 1993; Lagos-Quintana
et al., 2001; Lau et al., 2001; Lee and Ambros, 2001; Ruvkun, 2001). MiRNAs are
transcribed by POL II as loop-structured pre-miRNAs, processed by nuclear Drosha,
exported to the cytoplasm by exportin V, and cleaved into their mature forms by the Dicer/
Argonaute complex (Chang and Mendell, 2007). The Dicer complex allows miRNA to
recognize target mRNA by base-pairing with sequences in the 3′ untranslated regions of the
mRNAs. Complementary base-pairing results in target mRNA degradation, whereas
incomplete base-pairing results in target mRNA translational repression by physical
inhibition of the mRNA ribosomal protein translational machinery (Kloosterman and
Plasterk, 2006). A single miRNA can interact with and affect translation of hundreds of
target mRNAs, thus potentially producing dramatic effects on cellular expression and in a
tissue-specific manner (Lim et al., 2005; Chang and Mendell, 2007; Landgraf et al., 2007).
MiRNAs have also recently been shown to play a crucial role in nuclear reprogramming
(Lin et al., 2008), and normal ESC self-renewal and differentiation (Houbaviy et al., 2003;
Suh et al., 2004; Wang et al., 2007). In particular, key pluripotency-associated transcription
factors bind to promoters and enhance transcription of miRNA preferentially expressed in
ESC while silencing miRNA genes upregulated in differentiating cells (Marson et al., 2008).
Moreover, miRNAs are believed to orchestrate the developmental timing of cellular
differentiation (Giraldez et al., 2005; Brown et al., 2007; Chang and Mendell, 2007;
Martello et al., 2007; Neilson et al., 2007), including hematopoietic lineage specification
(Chen et al., 2004; Felli et al., 2005; Costinean et al., 2006; Garzon et al., 2006; Ramkissoon
et al., 2006; Bruchova et al., 2007; Choong et al., 2007; Fontana et al., 2007; Georgantas et
al., 2007; Thai et al., 2007; Xiao et al., 2007; Zhan et al., 2007). For example, regulation of
HOX genes is regulated by several miRNAs (Yekta et al., 2004). Aberrant miRNA
expression has also been established as an important pathway of tumorigenesis, including in
hematopoietic and germ cell malignancies (Eis et al., 2005; Voorhoeve et al., 2006). In
mice, several hematopoietic-specific miRNAs have been reported, including mir-223,
mir-142, and mir-181 (Chen et al., 2004). Additionally, ectopic expression of mir-155 in
adult murine hematopoietic progenitors results in profound effects on lymphopoietic
function (Thai et al., 2007). In human CD34+ cells, down-regulation of miRNA 221 and 222
occurs during erythropoietic differentiation (Felli et al., 2005).
Several groups have shown that miRNAs may play instructive roles in mesodermal
commitment of the embryo by directly controlling Nodal expression (Martello et al., 2007),
which plays a pivotal role in the induction and patterning of mesoderm, as reviewed above.
MiRNA regulation in epithelial to mesenchymal transition, which is key in gastrulation, has
also been identified (Gregory et al., 2008). In hESCs, two miRNAs, miR-1 and miR-133,
have been demonstrated to promote mesoderm formation by repressing non-muscle genes
but have opposing functions in subsequent differentiation to cardiac progenitors (Ivey et al.,
2008).
Although miRNAs clearly regulate developmental decisions, the regulatory role of miRNAs
during normal human embryonic development of HSC is currently impossible to study, and
the hESC differentiation system provides a valuable system for understanding their function.
The miRNA signature of human hemangioblasts and HSC has not yet been reported. A clear
role for miRNAs in hemangioblast development and differentiation should enlighten the
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developmental role of miRNAs in specifying the hematopoietic lineage. Furthermore, the
ectopic expression of miRNAs acting as mimics (Voorhoeve et al., 2006) or antagomirs
(anti-sense miRNA oligonucleotides) (Krutzfeldt et al., 2005) may augment or efficiently
direct differentiation of hESC to mesodermal-hematopoietic lineages.
The utility of hESC-derived hemangioblasts for generating therapeutically-
useful hematopoietic lineages
Understanding and mimicking the in vivo stem cell niches that generate hemangioblasts
during development, as outlined above, may eventually allow powerful methodologies for
generating therapeutically useful, patient-specific hemangioblasts from hESC/ iPSC. In vitro
hemangioblast differentiation may provide unique opportunities for regenerative medicine
by generating transplantable endothelial cells, HSC, megakaryocytes, lymphocytes, and
transfusable granulocytes and erythrocytes (Olsen et al., 2006). Endothelial progenitor cells
(EPCs), in particular, have received increased attention in recent years as the number of
adults affected by cardiovascular diseases continues to rise (Rosamond et al., 2008).
Researchers and clinicians hope to use EPCs to repair ischemic tissues, enhance blood
vessels and heart valves that could replace the need for coronary angioplasty or coronary
artery bypass graft surgery, which are currently used to repair damaged circulatory tissue
(Niklason, 1999; Liew et al., 2006). The derivation of patient-specific transfusable
erythrocytes, lymphocytes, and platelet-forming progenitors (megakaryocytes) from
pluripotent stem cells would also have enormous utility. However, the derivation of all these
therapeutically important lineages from human pluripotent stem cells currently all face
unique technical challenges.
Efficient generation of hESC-derived B- and T-lymphocytes, for example, could play an
important role in replenishing the immune system of patients suffering from severe
combined immunodeficiency or AIDS. Although they are derived from a common
progenitor, B- and T-lymphocytes develop in distinct sites in vivo and pose unique
challenges in deriving them from hESC. By recapitulating their in vivo development within
the bone marrow, for example, the growth of CD45R+CD19+ mature functional B cells from
both mESCs and hESCs has been achieved (Cho et al., 1999; Cho and Zuniga-Pflucker,
2003) via co-culture on bone marrow stromal cell lines such as S17, MS5, and OP9 (Collins
and Dorshkind, 1987; Landreth and Dorshkind, 1988; Itoh et al., 1989; Cumano et al.,
1990). The addition of FLT3L and IL-7 are crucial for this system’s efficient production of
B lymphocytes, although other cytokines, such as IL-4, have also been shown to augment
this process.
Cord blood (CB), fetal liver, bone marrow (BM), and peripheral blood CD34+ cells have all
been shown to be capable of generating T cells in vitro. Various methodologies, including
the use of thymic stroma, have been described toward this end (Hare et al., 1999; Plum et
al., 2000; LA MOTTE-MOHS et al., 2007). Clustering of human CD34+ CB cells with
murine fetal thymic epithelial cells in reaggregated thymic organ cultures (RTOC) implanted
into NOD/SCID mice gave rise to CD4+CD8+ immature double positive (DP) as well as
some functionally mature CD4+ and CD8+ single positive (SP) T-cells (Saito et al., 2002).
Murine thymic stromal cells have been used to seed matrices in a tissue-engineering
approach to produce T cells from human bone marrow derived hematopoietic progenitors
(Poznansky et al., 2000). Thymic stromal culture from rhesus macaques has also been used
for coculture with human CD34+ BM derived progenitor cells (Rosenzweig et al., 1996).
Fetal thymic organ culture (FTOC), in which human HPC are cocultured with fetal thymic
lobes from NOD-SCID mice, is a favored approach which, like all these systems, is useful
but produces only a very limited number of T cells (Jenkinson and Anderson, 1994; Tavian
et al., 2001).
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In vitro production of T-cells from ESC, however, has been more challenging due to
difficulties in recreating the unique thymic microenvironment (which plays a central role in
the sequential, temporal, and spatial in vivo development of these cells) which guides
primitive HSC toward T-cell differentiation. The discovery of the key role of Notch-Delta
signaling in the thymic stromal environment of the developing T cell led to the advent of the
OP9-DL1 ESC co-culture system. The ability of the OP9-DL1 system to expand and
maintain progenitor T cells allows it to be uniquely utilized for large-scale generation of
human T cells from various sources. OP9-DL1 cells support the generation of DP immature
T cells, as well as some CD8+ SP (but not as many CD4+) cells from mouse HSC or
differentiating mESC (from KDR/flk-1 populations, which contain murine hemangioblasts).
The system has also been used successfully with human CD34+ CB and bone marrow HSC
(Schmitt and Zuniga-Pflucker, 2002; Schmitt et al., 2004; La Motte-Mohs et al., 2005).
Recent attempts to generate lymphocytes from hESC-derived hematopoietic progenitor cells
using both the OP9-DL1 co-culture system as well as FTOC have met with limited success
(Martin et al., 2008). Since definitive HSC with lymphoid potential have been detected only
from human AGM, and not YS embryonic tissues (Tavian et al., 2001), these results are not
entirely surprising. They do, nonetheless, further highlight the necessity for methods that can
generate adult-type definitive HSC from hESC before large-scale production of T cells for
cell therapy will be possible.
One of the most promising applications of hESC hematopoietic differentiation technology is
the efficient large-scale production of red blood cells (RBC) for clinical transfusion (Olivier
et al., 2006). hESC-derived erythroid progenitors, which we and others have demonstrated
can arise directly from hESC-derived hemangioblasts, may provide a clinically useful and
standardized source of transplantable RBC for urgent surgeries, or for treatment of hemoglo-
binopathies such as sickle cell disease and alpha/beta thalassemias. In general, a simple
transfusion requires ~1–2.5×1012 red blood cells (500 ml of whole blood at 5×109 red blood
cells per ml) (Ma et al., 2008b). Since blood donations are often in short supply, a blood
bank with hESC-derived erythroid progenitor cells (for example from a pluripotent line
expressing the universal blood type O antigen) may provide an unlimited source of
transfusable erythrocytes. This goal would require hESC differentiation and subsequent
mass production of erythroid cells expressing definitive-type fetal- or adult beta globin-
expressing RBC, which has not yet been reported. Murine erythropoietic differentiation
systems have thus far proven more successful in the massive production of definitive,
transfusable RBC. mESC-derived erythroid progenitors (ES-EPs) with cell morphology,
growth and terminal differentiation characteristics similar to those of immature erythroid
progenitors found during in vivo stress erythropoiesis, were generated efficiently in the
presence of Epo, SCF, and glucocorticoids (Carotta et al., 2004). ES-EPs (Ter119+
cKit+CD71+ erythroblasts) could be expanded for over 70 days, and terminally
differentiated into enucleated erythrocytes. In a similar study, ES-EPs could ameliorate
acute anemia upon injection into affected mice, suggesting that EP from hESC could
similarly function in anemic disorders (Hiroyama et al., 2008).
Recent reports have confirmed the feasibility of massively expanding enucleated, human
RBC from hESC differentiated in suspension liquid cultures (e.g. ~109–1011 erythrocytes
from one six-well starting plate with ~3×106 cells hESC) (Lu et al., 2008). In these studies,
hEB-derived hemangioblasts were differentiated into mature, enucleated red blood cells with
oxygen equilibrium, pH and 1,3-diphosphoglycerate depletion responses analogous to those
of transfusable RBC. Although these erythroid cells expressed low levels of adult beta-
globin (~16%), and high levels of embryonic/fetal hemoglobins (thus indicating that they are
sill at a YS-like developmental phase), this large-scale production could potentially be
optimized for establishing and expanding erythroid progenitor lines with long-term
proliferation capacity. Although enucleated fetal-type definitive erythroid cells expressing
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the universal blood group O were generated in these studies, before such methodologies
could be used more practically for transfusions in clinical or medical research, efficient
protocols for the derivation of more mature adult type, beta-globin-expressing RBC will
need to be developed (as they have been for CB CD34+ cells (Neildez-Nguyen et al., 2002;
Giarratana et al., 2005; Miharada et al., 2006). The generation of such adult-type RBC from
ESC has generally depended on the recapitulation of the in vivo microenvironment found in
the FL and BM using cytokines, growth factors, and stromal cells. For example, liquid
culture of hESC-derived CD34+ cells in the presence of IL-3, BMP4, FLT3L, SCF and EPO
in a stage-specific manner during hematopoietic differentiation, and subsequent co-culture
on MS-5 feeder layers resulted in the formation of megaloblastic, nucleated erythroid cells
(Olivier et al., 2006). These cultures initially formed pro- and basophilic erythroblasts
expressing embryonic Gower I (ζ2 ε2 and Gower II α2 μ2. In another system, co-culture of
hESC-derived CD34+ cells on immortalized fetal liver stroma resulted in similar
erythroblast generation with expression of embryonic hemoglobins (Qiu et al., 2008).
Extended culture to 35 days produced enucleated erythrocytes with hemoglobin switching to
fetal hemoglobins (α2 ε2), and minimal (~2%) adult β-hemoglobin expression. In contrast,
formation of definitive erythroid colonies, bursts, and mixed colonies from hESC was
recently described using a mouse fetal liver stromal cell co-culture system (Ma et al.,
2008a). CFC assays at various developing timepoints from these co-cultures revealed
erythrocytes with rapidly increasing beta-globin expression (from 26% to ~100%), and
decreasing epsilon-globin expressions (from 100% to 50%). Comparison of hESC-derived
erythroid cells to definitive CB erythroid cells confirmed a similarity in their G6PD and
oxygen dissociation curves. These studies collectively demonstrate that transplantable adult-
typeRBC expressing adult hemoglobins could eventually be produced on a large scale from
human pluripotent stem cells.
Mass production of platelets using hESC derived-megakaryocytes (the platelet producing
cell of the human body) could alleviate the need for donors and allow the production of
unlimited supplies for treating the thrombocytopenia of chronic chemotherapy, or from
blood clotting disorders (e.g., Bernard-Souliér syndrome and Glanzmann thrombasthenia).
The OP9 stromal system may be useful for generating hESC-derived, functional
megakaryocytes. Several groups have already shown that ESC can readily be induced to
differentiate into such megakaryocytic progenitors using TPO and OP9 stroma to give rise to
functional cells secreting proplatelets and fibrinogen after exposure to platelet agonists (Era
et al., 2000; Eto et al., 2002; Eto et al., 2003; Fujimoto et al., 2003)
Furthermore, mass production of transfusable granulocytes could also supplement host-
deficient neutrophil production in congenital leukocyte function deficiencies, or
chemotherapy-induced myelosuppression (Saeki et al., 2008). 75% efficient neutrophil
production from mESC was first accomplished using a 3-step differentiation protocol. In this
system, formation of mEBs (8 days) followed by sequential co-culture of mEBs on OP9
stroma in medium containing a broad cocktail of hematopoietic growth factors, resulted in
the production of 107 neutrophils from 80,000 mESC (Lieber et al., 2003; Lieber et al.,
2004). Differentiation of hESC into neutrophils was similarly accomplished using a 2-step
feeder-free hEB-based differentiation method supplemented with hematopoietic growth
factors (Saeki et al., 2008), albeit at much lower efficiencies (4×106 neutrophils from
~4×106 hESC). These neutrophils expressed CD66b, CD16b, and GPI-80, had
morphological and cytochemical (myeloperoxidase and neutrophil alkaline phosphatase)
characteristics of mature neutrophils. hESC-derived granulocytes also exhibited neutrophil
characteristics of chemotactic activity, chemoattractant stimulation, production of reactive
oxygen species upon phagocytosis, and in vivo IL-1b-enhanced migration
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Patient-specific pluripotent stem cells can be generated via various
methods for the ultimate production of autologous hemangioblasts
A crucial step that remains to be elucidated before hESC can becomeclinically useful for
generating therapeutic hemangioblasts and HSC is the avoidance of the immune-mediated
rejection that will result upon transfer of allogeneic, hESC-derived cells into recipients. The
best way to circumvent this technical, yet critical caveat is to generate autologous, patient-
specific pluripotent stem cells that could subsequently be used for generating HSC.
Currently, three methodologies have been proposed to generate patient-specific pluripotent
cells: 1) parthenogenesis (PG), 2) somatic cell nuclear transfer (SCNT), and 3) induced
pluripotent stem cells (iPSC) (Fig. 5).
Parthenogenesis (PG)
This alternative asexual reproductive mechanism, which occurs in insects and reptiles, can
be exploited experimentally to produce a diploid embryo from an unfertilized, artificially-
activated oocyte (Cibelli et al., 2002; Cibelli et al., 2006). In mammals, PG-derived embryos
arrest at the limb bud stage due to the lack of essential paternal genomic imprinting of
critical genes required for proper development (Kono et al., 1996). Although limited in their
potential to undergo complete organogenesis, PG-derived pre-implantation embryos at the
blastocyst stage represent a valuable source of parthenogenetic ESC (pgESC) for research
purposes. These embryos can be used to produce pgESC lines that are substantially (but not
completely) genetically identical to the oocyte donor. Experimentally, oocytes can retain
diploidy via retention of a polar body using cytokinesis inhibitors and calcium ionophores
(Revazova et al., 2007; Revazova et al., 2008), or rarely via spontaneous duplication of the
haploid genome during subsequent development. pgESC from mice, monkeys, and humans
have been shown to retain characteristics of ESC including the ability to self-renew, to
contribute to chimeric animals, and to give rise to all three germ layers, including
hematopoietic mesoderm (Kaufman et al., 1983; Cibelli et al., 2002; Vrana et al., 2003;
Eckardt et al., 2007; Kim et al., 2007).
Since PG embryos are inherently defective in developing to full term, human PG-derived
hESC (pg-hESC) from donated oocytes arguably avoid many of the ethical and political
hurdles associated with the derivation of new hESC lines. Because PG embryos are derived
from an artificially activated oocyte in the absence of sperm, the resulting embryo and pg-
hESC line derived from it are remarkably similar to the oocyte donor, with a few exceptions
in distal loci from the centromeres where crossing-over occurred during meiosis I. It has
been shown that pg-hESC are as much as 90% identical, including all human leukocyte
antigens (HLA) loci, thus representing a source of autologous transplantable cells for female
oocyte donors, as well as their offspring. The derivation of pg-hESC with both heterozygous
and homozygous HLA alleles has recently been shown (Kim et al., 2007; Lin et al., 2007;
Mai et al., 2007; Revazova et al., 2007; Revazova et al., 2008). Thus, autologous
transplantable cells from pg-hESC have become are a potential resource for therapeutic
strategies for a number of diseases, including blood disorders.
HLA-homozygous genomes generated via PG will result in only three HLA markers for
tissue transplantation matching, in contrast to six HLA markers in heterozygous diploid
genomes. This has resulted in the proposal for the creation of a universal pg-hESC stem cell
that may ultimately serve the transplantation needs of large populations. Computational
models have predicted that a small number of such pg-hESC lines could provide a beneficial
match for the majority of the population (Taylor et al., 2005). A stem cell bank could
include HLA-homozygous pg-hESC lines, but also HLA-homozygous human adult
fibroblast cells (for the generation of iPSC; see below) derived from donors previously
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tested for a desired haplotype through the National Marrow Donor Program. However, such
banks will not be suitable for minority populations such as African-Americans (primarily
affected by sickle cell anemia), or other ethnic minorities (e.g. affected by beta-thalassemia)
with rare haplotypes.
However, the scarce availability of human oocytes, makes PG technically unpractical,
although PG embryos could potentially be generated from surplus mature metaphase II
oocytes donated in rare numbers as a by-product of in vitro fertilization (IVF). Alternatively,
pg-hESC could also be derived from excess immature germinal vesicle and metaphase I
oocytes, which are not suitable for reproductive technologies such as intracytoplasmic sperm
injection or IVF. Frozen, surplus oocytes, which are voluntarily donated by couples
routinely for research, could also potentially be utilized (Polak et al., 2007). Overall, other
alternative methods will likely ultimately prove more practical than pG for generating
autologous hESC for patients.
Somatic cell nuclear transfer (SCNT)
SCNT, which was first described ~sixty years ago by Briggs and King in classic frog
developmental studies, demonstrated that somatic cell nuclei transferred to enucleated
oocytes can be reprogrammed back into a pluripotent state, indicating that somatic
differentiation is a reversible process (Briggs and King, 1952). During the SCNT process,
nuclei extracted from adult somatic cells (e.g., fibroblasts) can reactivate pluripotency genes
that were previously silenced during cellular specification and differentiation following
exposure to oocyte cytoplasmic factors. Subsequent culture of these artificially-activated
pseudo-zygotes leads to the formation of a blastocyst, from which an inner cell mass can be
isolated to generate ESC that are genetically identical to the donor of the somatic cell
nucleus.
SCNT has now been demonstrated in a number of mammals since a cloned sheep (“Dolly”)
was first reported (Campbell et al., 1996). Although SCNT has a long history, it was only
recently demonstrated that SCNT-derived ESC could be generated from nonhuman primates
using adult male rhesus macaque fibroblasts as a donor nuclei source (Byrne et al., 2007).
Although these studies open avenues for generating patient-specific SCNT-derived hESC
for therapeutic cell therapies, a goal that yet remains to be achieved, SCNT inefficiency
(<1% in monkeys compared to 16% in parthenogenesis) requires a large number of oocytes
for this technique to be clinically applicable. Additionally, SCNT requires costly and
complex equipment making therapeutic cloning via SCNT an unlikely source to generate
autologous patient-specific hESC in the near future.
Induced pluripotent stem cells (iPSC)
The technical and ethical challenges associated with deriving hESC using SCNT and PG
have sparked alternative efforts for generating autologous pluripotent stem cells. One of the
most promising approaches has been the emergence of genetically-induced pluripotency.
During this process, somatic cells can be reprogrammed to a pluripotent-like state using
defined groups of retrovirally-expressed pluripotency-associated transcription factors (e.g.,
SOX2, OCT-3/4, KLF4, C-MYC, LIN28, and NANOG; SOKMLN), as first demonstrated
by Takahashi and Yamanaka using murine embryonic fibroblasts and SOKM (Takahashi
and Yamanaka, 2006; Okita et al., 2007; Takahashi et al., 2007a). These iPSC readily form
multi-lineage teratomas in NOD/SCID immunodeficient hosts, and contribute efficiently to
the development of fertile chimeric mice, thus demonstrating comparability to bona fide
ESC derived from blastocysts.
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This methodology quickly translated to human somatic cells including fibroblasts, MSC, and
keratinocytes, resulting in the first human iPSC, albeit at significantly lower frequencies
than in murine cells (Takahashi et al., 2007b; Yu et al., 2007; Nakagawa et al., 2008; Park et
al., 2008b). Derivation of iPSC lines from patients’ diseased somatic cells has recently
confirmed the feasibility of generating autologous iPSC lines for transplantation purposes
and disease modeling. Several diseased iPSC lines have already been generated, including
ones affected with Down syndrome, Parkinson’s disease, Huntington’s disease, and
Shwachman-Bodian-Diamond syndrome (Park et al., 2008a). Diseased iPSC have also been
derived from fibroblasts of an 82-year-old woman diagnosed with amyotrophic lateral
sclerosis. These iPSC could successfully be differentiated into motor neurons, which are
destroyed in ALS (Dimos et al., 2008).
Although the generation of patient-specific iPSC appears to resolve the problem of immune
rejection, a major problem in this technology is the serious potential for malignant
transformation of these pluripotent lines. This risk is considerable with the current use of
retro- and lentiviruses, since such vectors are prone to random insertional mutagenesis. In
particular, the use of the proto-oncogenes KLF4 and C-MYC in current iPSC cocktails is
problematic, since they have known potentials for malignant transformation. Indeed,
chimeric mice made with iPSC that were generated using these pluripotency factors as
transgenes eventually formed malignant tumors (Nakagawa et al., 2008). The oncogenicity
of iPSC can be reduced by using only OCT4, and either KLF4 or C-MYC (Kim et al., 2008),
or alternatively OCT4 and SOX2 transgenes alone, thus avoiding KLF4 and C-MYC
altogether (Huangfu et al., 2008b), but insertional mutagenic potential inherent in the use of
retroviral constructs will still remain a grave concern for ultimate clinical utility (Hacein-
Bey-Abina et al., 2003; McCormack and Rabbitts, 2004).
Recently published studies have already begun to address the caveats of iPSC derived by
first-generation methods. Using Cre-LoxP excisable lentiviral and transposon–inserted
transgenes, recent studies have demonstrated that persistent viral-integrated transgene
expression is not required for reprogramming somatic cells, and that vector-free iPSC can be
generated, albeit at lower efficiencies (Soldner et al., 2009; Woltjen et al., 2009).
Additionally, generation of human iPSC using nonintegrating constructs was also recently
reported (e.g., using recombinant adenoviruses (Stadtfeld et al., 2008), Epstein-Barr virus-
based episomal constructs (Yu et al., 2009), SOKM proteins fused with cell penetrating
peptides (CPPs) (Kim et al., 2009; Zhou et al., 2009), or repeated transfections of plasmids
harboring SOKM cDNAs (Okita et al., 2008)), thus confirming that reprogramming does not
rely on genomic integration or insertional mutagenesis. Although this field is now rapidly
progressing and holds great potential for ultimately producing clinically safe iPSC,
methodologies for further optimizing the currently low reprogramming process will still
need to be developed (Huangfu et al., 2008a).
Future Directions
Although the existence of the hemangioblast was first recognized almost a century ago
(Sabin, 1920; Murray, 1932), in vitro strategies for isolating, characterizing, or generating
human hemangioblasts, and adult-type, definitive hematopoietic cell lineages from them, has
thus far been elusive. The recent isolation and characterization of the human hemangioblast
from hESC has created new potential to further evaluate mechanisms by which
hemangioblasts and HSC could be generated, maintained, and expanded. It has become
apparent that complex in vivo developmental signaling pathways and environments will
need to be recapitulated to further mature these hESC-derived primitive progenitors into
adult blood cells before they can be practically used in regenerative medicine for a number
of hematological diseases.
PETERS et al. Page 21
Int J Dev Biol. Author manuscript; available in PMC 2012 November 30.
$watermark-text
$watermark-text
$watermark-text
Moreover, before hESC-derived hemangioblast and HSC can be used for clinical
applications, patient-specific pluripotent stem cells will first need to be generated with more
efficient, and ethically non-controversial methodologies than the current approaches that PG
or SCNT provide. Human iPSC, which solve some of these obstacles, will have to be
generated via methods that lack malignant potential, as was recently described using
nonintegrating episomal vectors (Okita et al., 2008; Stadtfeld et al., 2008; Yu et al., 2009) or
reprogramming proteins fused with CPPs (Kim et al., 2009; Zhou et al., 2009). Moreover,
despite their great similarities to hESC, it remains to be seen whether iPSC will hold
comparable, or perhaps even greater differentiating potential than hESC for generating
hematopoietic lineages (Choi et al., 2009; Lohetal., 2009). Finally, the differentiation of
hemangioblasts and HSC from diseased patient-specific iPSC will shed important biologic
insight into the developmental pathways and molecular nature of a number of hematologic
disorders.
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Fig. 1. Comparative schematic of normal human embryonic hematopoiesis and in vitro human
embryonic stem cell (hESC) differentiation
(A) Aorta-gonad-mesonephros (AGM) embryonic definitive hematopoiesis originates from
the lateral plate mesoderm, and gives rise to adult definitive-type hematopoietic stem cells
(HSC) capable of long-term lympho-hematopoietic engraftment in adult recipients. (B) In
contrast, primitive yolk sac (YS) hematopoiesis initiates from extra-embryonic mesoderm,
and is characterized by the formation of primitive hemangioblasts within YS blood islands
that provide ephemeral hematopoiesis for the developing embryo. (C) Human embryoid
body (hEB) differentiation recapitulates human YS development and gives rise to
mesodermal progenitors, hemangioblasts (BL-CFC), and YS-like primitive and definitive
blood cells in two sequential waves. (D) Angiotensin converting enzyme (ACE; CD143),
CD34, and CD43 gene expression are upregulated during hemangioblast development,
emerging hematopoietic stem cells, and embryonic hematopoietic cells, respectively
(Zambidis et al., 2008). (E) Normal human YS development appears to parallel the timeline
of our in vitro hEB hematopoietic differentiation system. hESC lines are derived from the
inner cell mass of a ~day 6 human blastocyst, and are maintained in an undifferentiated state
prior to hematopoietic hEB differentiation. During normal gestation, human YS
development directly follows formation of the primitive streak, and the extraembryonic
secondary YS layers at gestational days 12–13. The formation of primordial YS blood
islands first occurs at days 14–16, with subsequent generation of primitive erythro-
myelopoietic cell lines starting after 18–20 days. MHE clusters and ACE+ BL-CFC similarly
arise in our system at a corrected gestational timeline of ~12–13 days (6d of blastocyst age +
days 6–7 of hEB differentiation), which is when the human primitive streak first develops.
Subsequently, primitive erythropoiesis arises at a corrected timeline of ~14–16 days (6d of
blastocyst age + 8–10 days of hEB differentiation), which is the milestone for YS blood
island generation. Finally, definitive erythro-myelopoiesis arises in our system at a corrected
timeline of >18–20 days (6d of blastocyst age + 12–20 days of hEB differentiation), when
similar events occur in the human YS, prior to the onset of fetal circulation at about 21 days.
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Fig. 2. Recapitulation of normal embryonic erythropoietic development using in vitro human
embryonic stem cell (hESC) differentiation
Line H1 (WA01) hESC-derived hEB were differentiated into hematopoietic cells using SF
culture conditions in the presence of VEGF, BMP4, FGF2, and heparan sulfate (VBF2 as
above). Single-cell suspensions from day 9 and day 14 hEBs, as well as CD34+-enriched
neonatal cord blood (CB) cells (positive control for adult-type definitive colonies) were re-
cultured for colony-forming-cell (CFC) potential in methylcellulose medium. Brownish,
“Salmon-red” hemoglobinization was observed on primitive erythroid colonies (EryP, BFU-
e-P; left column) generated from day 7 to 12 hEBs, while day 12 to 20 hEBs erythroid
colonies (EryD, BFU-e-D; middle column) resembled definitive CD34+ CB blood cells
(BFU-e-D, CFU-e-D; right column). Surface marker expression by FACS analysis revealed
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that all types of erythoid CFCs had similar surface expression of CD71 and CD235a
(GlycophorinA) erythoid progenitor markers, but CD36, an erytho-myeloid lineage marker,
was only moderately expressed in EryP/ BFu-e-D, and the embryonic pan-hematopoietic
marker CD43 was mostly absent in EryP/ BFU-e-P, and only moderately expressed in BFU-
e-D/ CFU-e-D. Hemoglobin detection showed high levels of embryonic Hbε and fetal HbF,
but little adult HbA in EryP/ BFU-e-P. In contrast, BFU-e-D/ CFU-e-D express moderate
levels of all hemoglobins, while CB erythroid hemoglobin status is limited mostly to adult
HbA and HbF. Figure adapted from Zambidis et al., 2008, with permission.
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Fig. 3. Generation of short-term engrafting he-matopoietic progenitors from hESC-derived
hemangioblasts
(A) Clonogenic human blast colony-forming cell (BL-CFC) assays of hEB-derived ACE+
hemangioblasts. Clonal blast colony formation (BL-CFC assays) from single Line H1
(WA01) hEB cells was tested and optimized in serum-free (SF) methylcellullose medium
using growth factors known to expand mouse BL-CFC. Human blast colonies expanded
from day 6–10 hEB, and minimally required VEGF, FGF2, and TPO to proliferate. Mature
blast colonies differentiated into clusters of multipotent primitive-definitive
CD43+CD45+CD41+ progenitors, and contained clonal progenitors for primitive YS-like
GlyA+ CD45− erythroid cells and endothelium following reculture into serumfree and
stromal-free culture conditions; or definitive GlyA+ CD45+ erythro-my-eloid cells if
alternatively cultured on OP9 bone marrow stromal layers. Figure adapted from Zambidis et
al., 2008, with permission. (B–D) Generation of engraftable CD34+CD45+CD38− adult-type
definitive-type he-matopoietic progenitors from ACE+ hEB-derived human hemangioblasts
following in vitro maturation on mesenchymal stro-mal niches, or in vivo injection into
mouse neonatal livers. (B) Day 9 to 10 FACS-sorted ACE+ CD34+ and ACE+ CD43+ hEB
populations (from Line H1 (WA01)) containing hemangioblasts were cultured on human
mesenchymal stromal cells (hMSC), and supplemented with human hematopoietic growth
factors. This co-culture system differentiated YS-like ACE+CD34+ hEB cells into ”
cobblestone ” - appearing CD34+CD45+CD38− cells that generated abundant definitive CFU
in meth-ylcellulose assays (GEMM-CFC, GM-CFC, and M-CFC shown, as well as G-CFC,
BFU-e, CFU-e) that were indistinguishable from CD34+ cord blood (CB) control colonies.
(C) These hEB-derived erythroid CFU resembled CB BFU-e in morphology and adult
hemoglobin expression with low intracyto-plasmic embryonic globin (epsilon), and high
amounts of fetal (gamma) and adult globin (beta) expressions. (D) Analysis of in vivo
maturation of hEB-derived cells following injection of stroma-differentiated hEB into the
neonatal liver of highly immunodeficient, irradiated (150 Gy) NOD/SCID/IL2Rgnull(NOG)
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mice (n=4). At 12 weeks, there was evidence for multi-lineage lympho-erythro-myeloid
engraftment; peripheral blood (PB) FACS analysis detected high levels of mouse erythroid
marker Ter119 and human CD41a (hCD41a), a megakaryocyte marker. Double positive
hCD4+CD8+ hematopoietic cells in the thymus demonstrated mature T cell maturation/
engraftment, while low levels of detectable hCD34, hGlycophorin A (CD235a), and hCD56
were found in the bone marrow of transplanted NOG mice.
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Fig. 4. Mesodermal morphogens and hematopoietic growth factors mediate agonistic and
antagonistic effects on hEB hematopoietic differentiation potential
Line 1 (WA01) hEB were cultured in non-adherent serum-free (SF) suspension cultures in
the presence of absence of VEGF, BMP4, and FGF2 (VBF2) starting on day 2 until day 9
(Stage I). On day 9, hEB were recultured as single cells onto gelatinized tissue culture plates
in SF medium and supplemented with 50 ng/ml of the inductive or inhibitory hematopoietic
growth factors Nodal, Wnt3a, IGFII, or Activin A (ActA) for 5 days (Stage II). Single cell
suspensions of Day 14 hEB were evaluated for Colony-Forming-Cell (CFC) potential in
serumfree H4436 SF methylcellulose containing hematopoietic growth factors. Total CFU,
mutipotent CFU (MHE, Mixed-P, and Mixed-D), primitive erythroid (BFU-e-P, EryP),
definitive erythroid (CFU-e-D, BFu-e-D), and myeloid (macrophage/monocyte) CFU
formation was recorded. In comparison to basal VBF2, further addition of Nodal, a
mesoderm inducer, enhanced the generation of all CFC except monocyte/ macrophage CFU.
Wnt3a, a downstream effector of Nodal, acted as a moderate agonist during mutlipotent
CFU formation, but drastically reduced definitive erythropoiesis. IGFII, another key player
in mesodermal differentiation, moderately augmented multipotent CFU and primitive and
definitive erythropoiesis. On the other hand, Activin A (ActA) dramacially abolished
hematopoietic CFU.
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Fig. 5. Methods for generating autologous, patient-specific pluripotent stem cells for therapeutic
cell transplantation
Parthenogenesis (PG), somatic cell nuclear transfer (SCNT), and induced pluripotent stem
cells (iPSC) have been proposed as the three technologies by which patient-specific
pluripotent stem cells could be generated for the generation of transplantable patient-specific
progenitors, including hemangioblasts. The process of PG requires chemical activation of a
patient’s isolated oocyte to proceed to the blastocyst stage, at which point embryonic stem
cells can be isolated for subsequent therapeutic generation of somatic cells. Comparatively,
SCNT also requires the use of an oocyte, but in an enucleated state. Transfer of a patient’s
somatic cell nucleus into the cytoplasm of the nucleus, resets the engineered cell to a
pluripotent state. Induced pluripotency reprograms a somatic cell into a pluripotent state in
the absence of an oocyte or a blastocyst intermediate by genetically transmitting defined
pluripotency factors that can reprogram somatic cells to an embryonic stem cell-like state.
Pluripotent stem cells generated by any of these methods can be differentiated into all cell
types of the body. Progenitor cells from various lineages (e.g. blood, pancreas, heart,
neurons, and liver) generated from patient-specific pluripotent stem cells can be transplanted
back into the donor as autologous cell grafts without fear of immune rejection.
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